| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/02/2006 | US7037718 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof |
| 05/02/2006 | US7037709 Comprises nucleotide sequences coding microsomal enzymes for detoxification of xenobiotic compounds in liver; drug screening; gene therapy |
| 05/02/2006 | US7037700 Regulation of human ceramide kinase |
| 05/02/2006 | US7037697 Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD and use of the said SOD in cosmetic, food, and pharmaceutical compositions |
| 05/02/2006 | US7037685 Nucleotide sequence coding polypeptide for use in the treatment and prevent of viral diseases, infections and tumors |
| 05/02/2006 | US7037684 Insertion Bacillus; culture product; transformation |
| 05/02/2006 | US7037683 Human longevity assurance protein, its coding sequence and their use |
| 05/02/2006 | US7037678 Protein for use in the treatment and prevention of cell proliferative disorders |
| 05/02/2006 | US7037677 Megakaryocytic protein tyrosine kinase I |
| 05/02/2006 | US7037668 Methods for the treatment and diagnosis of tumorigenic and angiogenic disorders using 32616 |
| 05/02/2006 | US7037666 Contacting latency-associated peptide- beta 1 (LAP- beta 1) or a functional variant thereof and integrin alpha v beta 3 or a functional variant thereof with test product under conditions that, in absence of test product, would permit interaction |
| 05/02/2006 | US7037665 Compositions comprising SNORF36 receptor compounds |
| 05/02/2006 | US7037516 comprises nonionic surfactants such as polyoxyethylene-stearate for sustaining elevated milk production response in lactating mammals; improved bioavailability |
| 05/02/2006 | US7037510 Hybrids of M. tuberculosis antigens |
| 05/02/2006 | US7037509 Immunologically significant herpes simplex virus antigens and methods for using same |
| 05/02/2006 | US7037507 T helper cell epitopes |
| 05/02/2006 | US7037505 interlkeukins (IL-8); tumor necrosis factor (TNF); improved cytokine activity, immune response |
| 05/02/2006 | US7037504 Resistant to proteolysis, and gene sequences encoding these forms and having codons optimized for usage by an industrial production organism, are provided. |
| 05/02/2006 | US7037502 Peptide for use in the treatment of inflammation |
| 05/02/2006 | US7037501 Administering to the egg- laying vertebrate or to an egg of the vertebrate the vaccine of immunoconjugate of myostatin polypeptide linked to a carrier to increase muscle weight |
| 05/02/2006 | US7037496 Chimeric immunoglobulin for CD4 receptors |
| 05/02/2006 | US7037495 Antimicrobial compositions |
| 05/02/2006 | US7037493 Method of inducing neuronal production in the brain and spinal cord |
| 05/02/2006 | US7037450 Production scale method of forming microparticles |
| 05/02/2006 | CA2490601C Method for preparing solid dosage form of desmopressin |
| 05/02/2006 | CA2149529C Peptides and anti-sense peptides with broad neoplastic specificity |
| 04/27/2006 | WO2006045066A2 Labeled compounds for proteasome inhibition |
| 04/27/2006 | WO2006044984A1 Inhibition of tumor growth and metastasis by atf2-derived peptides |
| 04/27/2006 | WO2006044825A2 Mitotic kinesin inhibitors and methods of use thereof |
| 04/27/2006 | WO2006044738A2 Methods and compositions for treatment of free radical injury |
| 04/27/2006 | WO2006044614A2 Anti-angiogenic peptides and methods of use thereof |
| 04/27/2006 | WO2006044582A2 Use of baff to treat sepsis |
| 04/27/2006 | WO2006044577A1 Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle |
| 04/27/2006 | WO2006044529A1 Compositions containing lipase; protease and amylase for treating pancreatic insufficiency |
| 04/27/2006 | WO2006044512A1 Fibronectin-modified ecm tissue graft constructs and methods for preparation and use thereof |
| 04/27/2006 | WO2006044410A2 A32 monoclonal antibody fusion proteins for use as hiv inhibitors and vaccines |
| 04/27/2006 | WO2006044391A1 A method of reducing drug-induced adverse side effects in a patient |
| 04/27/2006 | WO2006044335A2 Therapy with clostridium perfringens enterotoxin to treat ovarian and uterine cancer |
| 04/27/2006 | WO2006044334A2 Platelet-derived growth factor compositions and methods of use thereof |
| 04/27/2006 | WO2006044333A2 Methods and materials for the inhibition of transplant rejection |
| 04/27/2006 | WO2006044330A2 Anticancer compounds and methods |
| 04/27/2006 | WO2006044294A2 Human protein c analogs |
| 04/27/2006 | WO2006044115A2 Method of treating parkinson's disease by convection-enhanced infusion of glial cell-line derived neurotrophic factor (gdnf) to the putamen |
| 04/27/2006 | WO2006044090A2 Topical treatment with ngf and dha in damaged corneas |
| 04/27/2006 | WO2006043615A1 Use of immunesuppressant receptor |
| 04/27/2006 | WO2006043060A2 Mam domain containing protein |
| 04/27/2006 | WO2006043036A2 Treatment of diabetes |
| 04/27/2006 | WO2006043031A2 Class iii slrp for the treatment of cancer |
| 04/27/2006 | WO2006042745A2 Chemically modified peptide analogs |
| 04/27/2006 | WO2006042655A1 Desoxo-nonadepsipeptides |
| 04/27/2006 | WO2006042654A1 Substituted nonadepsipeptides |
| 04/27/2006 | WO2006042653A1 Heterocyclyl-substituted nonadepsipeptides |
| 04/27/2006 | WO2006042626A1 Depilation agent or color-changing or shape-changing fiber treatment agents with active substances for stimulating the release of $g(b)-endorphin in keratinocytes |
| 04/27/2006 | WO2006042558A2 Group 2 mite polypeptide variants |
| 04/27/2006 | WO2006042408A1 Gh secretagogues and uses thereof |
| 04/27/2006 | WO2006042403A1 Process for producing natural immunobiotic extract and uses thereof |
| 04/27/2006 | WO2006027545A3 Method |
| 04/27/2006 | WO2006023795A3 Amphipathic proteinaceous coating on nanoporous polymer |
| 04/27/2006 | WO2006023396A3 Vla-4 antagonists |
| 04/27/2006 | WO2006020884A3 Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors |
| 04/27/2006 | WO2006018551A8 Novel peptide and pharmaceutical composition containing said peptide |
| 04/27/2006 | WO2006007529A9 Immunosuppressive exosomes |
| 04/27/2006 | WO2006002453A3 Use of a deubiquitinating compound for enhancing the expression of membrane proteins on the cell surface |
| 04/27/2006 | WO2005123112A3 Method of enhancing the immune response to a vaccine |
| 04/27/2006 | WO2005123104A3 Use of vegf inhibitors for the treatment of human cancer |
| 04/27/2006 | WO2005121329A3 Method for ameliorating an inflammatory skin condition |
| 04/27/2006 | WO2005118627A3 Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use |
| 04/27/2006 | WO2005118611A3 Microutrophin and uses thereof |
| 04/27/2006 | WO2005117848A9 Vascular targets for detecting, imaging and treating neoplasia or neovasculature |
| 04/27/2006 | WO2005113586A3 Disease-associated proteins |
| 04/27/2006 | WO2005101004A3 Diagnostics and therapeutics for diseases associated with purinoceptor 1 type y (p2y1) |
| 04/27/2006 | WO2005100390A3 Bob-1 specific t cells and methods to use |
| 04/27/2006 | WO2005094348A3 Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer |
| 04/27/2006 | WO2005094269A3 Mucolytic and anti-elastase compounds and methods of use thereof |
| 04/27/2006 | WO2005092918A3 Targeting polypeptide |
| 04/27/2006 | WO2005092365A3 Pharmaceutical use of novispirins |
| 04/27/2006 | WO2005090385A3 Compositions having antimicrobial activity and uses thereof |
| 04/27/2006 | WO2005087792A3 Materials and methods relating to the treatment of glioblastomas |
| 04/27/2006 | WO2005086825A3 Methods and compositions for treatment of diseases associated with aberrant microsatellite expansion |
| 04/27/2006 | WO2005072241A3 Inhibition of bright function as a treatment for excessive immunoglobulin production |
| 04/27/2006 | WO2005027884A3 Stabilized ocular solutions |
| 04/27/2006 | WO2004094592A3 Polymer-conjugated glycosylated neublastin |
| 04/27/2006 | WO2004087072A3 Topical l-carnitine compositions |
| 04/27/2006 | WO2004069152A3 Δ4,5 glycuronidase and uses thereof |
| 04/27/2006 | WO2004005486A3 Mp21s as modifiers of the p21 pathway and methods of use |
| 04/27/2006 | WO2003040333A3 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof |
| 04/27/2006 | WO2003033665A3 Secreted protein, ztnf9 |
| 04/27/2006 | US20060090213 Transgenic mice containing Kir5.1 inwardly rectifying potassium channel gene disruptions |
| 04/27/2006 | US20060090212 Novel human genes and proteins encoded thereby |
| 04/27/2006 | US20060089490 Survival motor neuron (SMN) gene: a Gene for spinal muscular atrophy |
| 04/27/2006 | US20060089488 Artificially synthesized antimicrobial peptide having antimicrobial property against at least one type of bacteria, where peptide comprises an amino acid sequence composed of at least part of a nuclear diffusion inhibitory signal sequence included in Rev-protein derived from human immunodeficiency virus |
| 04/27/2006 | US20060089346 Optionally fused aryl-substituted azepanones, oxazepanone or thiazepanones substituted with a dipeptide group, e.g., N2-[(3,5-difluorophenyl)acetyl]-N1-[(2R,3R)-2-(2,5-difluorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide; secretase inhibitors for treating Alzheimer's disease |
| 04/27/2006 | US20060089325 Antisense modulation of PTP1B expression |
| 04/27/2006 | US20060089322 Antisense oligonucleotides for identifying drug targets and enhancing cancer therapies |
| 04/27/2006 | US20060089320 Modulation of type IIß phosphoinositide phosphate kinase |
| 04/27/2006 | US20060089314 Image heating apparatus and method for manufacturing image heating apparatus |
| 04/27/2006 | US20060089313 Methods and compositions for ameliorating the undesirable effects of chemotherapy |
| 04/27/2006 | US20060089312 Protease inhibitors |
| 04/27/2006 | US20060089311 Agonists and antagonists of ryzn for the treatment of metabolic disorders |
| 04/27/2006 | US20060089310 Treatment of infections and other disorders |